MedAcuity and Haply Robotics have entered into a strategic partnership to drive forward innovation in precision haptics for medical and robotic technologies. By combining Haply's pioneering haptic interface solutions with MedAcuity's expertise in regulatory-grade software development, the collaboration will focus on creating next-generation teleoperation systems designed for surgical, diagnostic, and simulation use. The partnership aims to deliver real-time, high-accuracy tactile feedback systems that enhance control, safety, and performance across remote medical and robotic applications.
MedAcuity, a leading software engineering company specialising in complex medical and robotic systems, has announced a strategic partnership with Montréal-based Haply Robotics, a global innovator in haptic and robotic interface technologies. Together, the two firms will accelerate the development of advanced teleoperated systems that unite precision engineering with state-of-the-art haptic feedback, transforming the landscape of remote healthcare, simulation, and training experiences.
The partnership integrates Haply's industry-leading technologies--including the award-winning Inverse3X and MinVerse devices--with MedAcuity's depth of knowledge in software architecture, systems integration, and regulatory-compliant development. By fusing cutting-edge tactile technologies with robust, safety-critical software, the collaboration will deliver systems designed to optimise operator control, fidelity, and reliability in high-stakes scenarios.
"This collaboration represents a natural alignment of strengths," said Dennis Fuccione, President of MedAcuity. "Haply Robotics is at the forefront of human machine interaction, and together, we are poised to push the boundaries of what's possible in remote robotic control and medical device innovation."
"Partnering with MedAcuity allows us to bring our advanced haptic technologies into new domains where precision and reliability are critical," said Colin Gallacher, President of Haply Robotics. "Their proven track record in regulated medical and robotic systems complements our mission to deliver intuitive, tactile experiences that elevate human control in remote environments. Together, we're enabling a new standard for human machine interaction."
Under this collaboration, the companies will jointly develop a portfolio of applications encompassing robotic-assisted surgery, remote diagnostics, and immersive simulation training. Each solution will be built with an emphasis on providing real-time, high-fidelity tactile feedback to enhance user precision, responsiveness, and confidence.
As industries increasingly demand more intuitive and responsive human–robot interfaces--particularly within telemedicine, defence, and industrial automation--the MedAcuity–Haply partnership is well-positioned to lead the next phase of innovation in haptic and teleoperated technologies.
source:newsreleases.co.uk
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA